Arcadia Biosciences (RKDA)
(Delayed Data from NSDQ)
$2.76 USD
-0.09 (-2.99%)
Updated Sep 10, 2024 03:59 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Income Statements
Fiscal Year end for Arcadia Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 5 | 10 | 7 | 8 | 1 |
Cost Of Goods | 3 | 10 | 9 | 5 | 1 |
Gross Profit | 2 | 0 | -2 | 3 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 16 | 19 | 34 | 16 | 20 |
Income After Depreciation & Amortization | -14 | -19 | -36 | -13 | -19 |
Non-Operating Income | 1 | 3 | 19 | 7 | -9 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -13 | -16 | -16 | -6 | -29 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | -1 | -1 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -13 | -16 | -16 | -6 | -29 |
Extras & Discontinued Operations | -1 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -14 | -15 | -15 | -5 | -29 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -13 | -17 | -28 | -11 | -19 |
Depreciation & Amortization (Cash Flow) | 1 | 2 | 7 | 2 | 1 |
Income After Depreciation & Amortization | -14 | -19 | -36 | -13 | -19 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.24 | 0.60 | 0.53 | 0.25 | 0.16 |
Diluted EPS Before Non-Recurring Items | -11.02 | -26.08 | -52.00 | -64.80 | -134.80 |
Diluted Net EPS (GAAP) | -11.30 | -25.65 | -27.60 | -18.80 | -181.20 |
Fiscal Year end for Arcadia Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 1.31 | 1.26 | 0.83 | 1.60 | 1.39 |
Cost Of Goods | 0.63 | 0.82 | 0.39 | 1.10 | 0.98 |
Gross Profit | 0.67 | 0.44 | 0.44 | 0.50 | 0.41 |
SG&A, R&D, and Dept/Amort Expenses | -1.31 | 3.50 | 3.30 | 3.74 | 4.20 |
Income After SG&A, R&D, and Dept/Amort Expenses | 1.98 | -3.06 | -2.86 | -3.24 | -3.79 |
Non-Operating Income | -0.13 | 0.64 | 6.30 | 0.76 | 4.61 |
Interest Expense | 0.00 | 0.00 | 0.20 | 0.00 | 0.00 |
Pretax Income | 1.85 | -2.42 | -2.11 | -2.48 | 0.82 |
Income Taxes | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 1.85 | -2.42 | -2.12 | -2.48 | 0.82 |
Extras & Discontinued Operations | -0.79 | 0.00 | -0.74 | -0.08 | 0.00 |
Net Income (GAAP) | 1.06 | -2.42 | -2.85 | -2.57 | 0.82 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 1.36 | 1.36 | 1.36 | 1.36 | 1.36 |
Diluted EPS Before Non-Recurring Items | 0.78 | -1.78 | -2.48 | -1.83 | -2.64 |
Diluted Net EPS (GAAP) | 0.78 | -1.78 | 0.84 | -1.89 | 0.61 |